Twist Bioscience Company (Mud) Q1 2026 Earnings Name February 2, 2026 8:00 AM EST
Firm Members
Angela Bitting – Chief Company Duty Officer & Senior VP of Company Affairs
Emily Leproust – Co-Founder, Board Chair & CEO
Patrick Finn – President & COO
Adam Laponis – Chief Monetary Officer
Convention Name Members
Matthew Larew – William Blair & Firm L.L.C., Analysis Division
Subhalaxmi Nambi – Guggenheim Securities, LLC, Analysis Division
Douglas Schenkel – Wolfe Analysis, LLC
Mackenzie Strehle
Brendan Smith – TD Cowen, Analysis Division
Steven Etoch – Stephens Inc., Analysis Division
Presentation
Operator
Women and gents, thanks for standing by. Welcome to Twist Bioscience Fiscal 2026 First Quarter Monetary Outcomes Convention Name. (Operator Directions) Please be suggested that immediately’s convention is being recorded. I would love now to show the convention over to Angela Bitting, Senior Vice President of Company Affairs. Please go forward.
Anthela Biting
Chief Company Duty Officer & Senior VP of Company Affairs
Thanks, operator. Good morning, everybody. I wish to thanks for becoming a member of us for Twist Biosciences convention name to assessment our fiscal 2026 first quarter monetary outcomes and enterprise progress. We issued our monetary outcomes press launch earlier than the market, and it’s out there at our web site at www.twistbioscience.com.
With me on the decision immediately are Dr. Emily Leproust, CEO and Co-Founding father of Twist; Adam Laponis, CFO of Twist; and Dr. Patrick Finn, President and COO of Twist. Right now, we are going to focus on our enterprise progress, monetary and operational efficiency in addition to progress alternatives. We are going to then open the decision for questions. We ask that you simply restrict your inquiries to just one after which requeue as a courtesy to others on the decision. This name is being recorded. The audio portion might be archived within the Traders part of our web site and might be out there for two weeks.